Opthea Limited Unsponsored ADR $OPT Position Reduced by Baker BROS. Advisors LP

Key Points

• Baker BROS. Advisors LP has reduced its stake in Opthea Limited Unsponsored ADR by 4.0%, owning 2,087,320 shares after selling 86,302 shares.
• Regal Partners Ltd significantly increased its position by 78.6%, now holding 5,193,688 shares, while other institutional investors also bought shares in Opthea.
• Opthea's stock has a 52-week range between $1.79 and $6.30, currently trading at $3.41.

Baker BROS. Advisors LP cut its position in shares of Opthea Limited Unsponsored ADR (NASDAQ:OPT - Free Report) by 4.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,087,320 shares of the company's stock after selling 86,302 shares during the quarter. Baker BROS. Advisors LP owned 1.36% of Opthea worth $7,118,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Regal Partners Ltd lifted its position in shares of Opthea by 78.6% in the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company's stock worth $17,710,000 after purchasing an additional 2,286,285 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Opthea in the fourth quarter worth approximately $556,000. Citadel Advisors LLC purchased a new stake in shares of Opthea in the fourth quarter worth approximately $79,000. Finally, OLD Mission Capital LLC lifted its position in shares of Opthea by 78.7% in the first quarter. OLD Mission Capital LLC now owns 19,167 shares of the company's stock worth $65,000 after purchasing an additional 8,439 shares in the last quarter. 55.95% of the stock is owned by hedge funds and other institutional investors.

Opthea Price Performance

NASDAQ OPT opened at $3.41 on Tuesday. The company has a 50 day simple moving average of $3.41 and a 200-day simple moving average of $3.52. Opthea Limited Unsponsored ADR has a 52-week low of $1.79 and a 52-week high of $6.30.

Opthea Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Want to see what other hedge funds are holding OPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opthea Limited Unsponsored ADR (NASDAQ:OPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.